Mark Enyedy, ImmunoGen CEO
May 3, 2023 11:22 AM EDTUpdated 02:28 PM
R&D

Im­muno­Gen’s ovar­i­an can­cer treat­ment helps pa­tients live longer than chemo in con­fir­ma­to­ry tri­al

Lei Lei Wu

News Reporter

In No­vem­ber, the FDA grant­ed ac­cel­er­at­ed ap­proval to Im­muno­Gen’s drug Ela­here for ad­vanced ovar­i­an can­cer — the first new treat­ment for the dis­ease in at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times